Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy.
BACKGROUND
Inflammatory markers are involved in heart failure (HF) pathophysiology. However, the link between these markers and reverse remodeling as well as major adverse cardiac events (HF death, sudden death, and unplanned cardiac rehospitalizations) in patients who undergo cardiac resynchronization therapy (CRT) has not been evaluated.


RESULTS
We recorded major adverse cardiac events of 140 patients (on optimized medical therapy, left ventricular ejection fraction 29.9 +/- 9.6%, New York Heart Association Class III-IV, with intraventricular dyssynchrony) who underwent CRT (enrolled since April 2004). Moreover, we evaluated before and after 6 months of CRT: interleukin-6, high-sensitivity C-reactive protein, New York Heart Association class, quality of life (score on Minnesota Living with Heart Failure questionnaire), 6-minute walking test, left ventricular end-diastolic and end-systolic volumes (nonindexed and indexed by body surface area), and left ventricular ejection fraction. Adverse cardiac events were observed in 40 patients (28.6%): 22 deaths and 18 cardiac unplanned rehospitalizations. Only patients without adverse events during follow-up showed a significant reduction of inflammatory markers and left ventricular volumes (reverse remodeling), despite a significant improvement of clinical status observed in both groups of patients.


CONCLUSIONS
The reduction of inflammatory status seems to be linked to reverse remodeling as well as to a better clinical prognosis in patients with HF who underwent CRT.
Michelucci
Antonio
A
Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy.
Ricciardi
Giuseppe
G
Sofi
Francesco
F
Gori
Anna Maria
AM
Pirolo
Francesca
F
Pieragnoli
Paolo
P
Giaccardi
Marzia
M
Colella
Andrea
A
Porciani
Maria Cristina
MC
Di Biase
Luigi
L
Padeletti
Luigi
L
Abbate
Rosanna
R
Gensini
Gian Franco
GF
D015415:Biomarkers / Q000378:metabolism; D002304:Cardiac Pacing, Artificial; D017079:Exercise Tolerance; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy*; D006334:Heart Function Tests; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D011379:Prognosis; D020257:Ventricular Remodeling
D015415:Biomarkers